Pegfilgrastim Biosimilars Market, By Product (Pegfilgrastim Biosimilars and Pegfilgrastim Reference Product), By Application (Oncology, Chronic Neutropenia, Stem Cell Transplantation, Others), By Route of Administration (Subcutaneous and Intravenous), By

Pegfilgrastim is a long-acting form of filgrastim that stimulates the bone marrow to produce more white blood cells. Pegfilgrastim biosimilars are follow-on biologics or subsequent entry biologics of pegfilgrastim. These biosimilars have no clinically meaningful differences in terms of safety, purity, and potency from the original version of pegfilgrastim, when administered at the same dose. Biosimilars provide a cost-effective alternative to innovative biologics and expand access to important medicines for patients. Global pegfilgrastim biosimilars growth is driven by increasing demand for affordable treatment options and the patent expiration of innovator drugs, thus, leading to market entry of multiple biosimilars.

Market Dynamics:

Global pegfilgrastim biosimilars market growth is driven rising prevalence of cancer cases globally. Growing awareness about biosimilar drugs and government thrust on increasing affordability of treatment have boosted adoption of pegfilgrastim biosimilars. Lower costs compared to reference biologics also drives the market growth. However, presence of stringent regulations for biosimilar approval can pose challenge for market players. Data exclusivity granted to reference drugs also delays market entry of biosimilars. Furthermore, complex production processes and the need for specialized expertise can hamper the market growth. Presence of strong pipeline with various biosimilar approvals and emerging markets can offer opportunities for market growth.

Key features of the study

• This report provides in-depth analysis of the global pegfilgrastim biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pegfilgrastim biosimilars market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen, AryoGen Pharmed, Coherus Biosciences, Mylan, Dr Reddy's Laboratories, and Biocon
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global pegfilgrastim biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pegfilgrastim biosimilars market

• By Product
• Pegfilgrastim Biosimilars
• Pegfilgrastim Reference Product
• By Application
• Oncology
• Chronic Neutropenia
• Stem Cell Transplantation
• Others
• By Route of Administration
• Subcutaneous
• Intravenous
• By Distribution Channel
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• CoherusBioSciences
• Mylan N.V.
• Biocon
• Sandoz (a Novartis division)
• Pfizer Inc.
• Apotex Inc.
• Cinfa Biotech
• Gedeon Richter
• StadaArzneimittel AG
• Mundipharma
• Aurobindo Pharma
• Glenmark Pharmaceuticals
• Reddy's Laboratories
• Intas Pharmaceuticals
• Biocad
• Genor Biopharma
• Qilu Pharmaceutical
• Henlius Biotech